An Open Label Registry Study of Lutetium-177 (DOTA0, TYR3) Octreotate (Lu-DOTA-TATE) Treatment in Patients with Somatostatin Receptor Positive Tumours

NCT02236910 · clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
66
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's